Navigation Links
InterMune Appoints Angus C. Russell to Board of Directors
Date:10/31/2011

BRISBANE, Calif., Oct. 31, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Angus C. Russell, Chief Executive Officer of Shire plc, has been appointed to InterMune's Board of Directors.  Shire is a leading global biopharmaceutical company focused on meeting the needs of the specialist physician.

"Angus Russell has successfully led Shire's evolution to a leading global biopharmaceutical company with expertise in the development and commercialization of specialty medicines," said Dan Welch, Chairman, Chief Executive Officer and President of InterMune.  "We look forward to drawing on his experience as we execute the launch of Esbriet in Europe, prepare to launch Esbriet beyond Europe and advance our other programs targeted on pulmonary and fibrotic diseases."  

Angus Russell has served as Chief Executive Officer at Shire since June 2008.  He is also the Chairman of Shire's Leadership Team and was a lead member of the Shire Management Committee that devised and implemented Shire's long-term, focused business strategy.  Prior to his current role, Mr. Russell was Chief Financial Officer at Shire from 1999 to 2008.  

Previous to joining Shire, Mr. Russell served at ICI, Zeneca, and AstraZeneca for 19 years, most recently as Vice President of Corporate Finance at AstraZeneca PLC.  In that role he was responsible for financial input into merger and acquisition activities, management of tax, legal and finance structure, investor relations, and the management of various financial risks.  Mr. Russell also held a number of positions within Zeneca Group PLC from 1993 until 1999, including Group Treasurer.  He is a chartered accountant, having qualified with Coopers & Lybrand (now PricewaterhouseCoopers LLP).

Mr. Russell is a member of the Board of Directors of Shire and also serves as a Member of the Advisory Board of Celtic Pharma Management L.P., a private equity advisement firm.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements  

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including statements related to the commercial launch of Esbriet and InterMune's clinical development plans.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 9, 2011 and other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InterMune to Release Third Quarter Financial Results on November 3
2. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
3. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
4. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
5. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
6. InterMune to Present at J.P. Morgan Healthcare Conference
7. InterMune Reports Third Quarter 2010 Financial Results
8. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
9. InterMune to Release Second Quarter Financial Results on July 27
10. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
11. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  As people age, it ... multitude of recommended screenings and tests that are linked ... priority. However, for the majority of aging individuals, hearing ... planning. For the 37.5 million American adults who report ... present to make hearing health a 2016 healthy aging ...
(Date:2/5/2016)... 2016 http://www.researchandmarkets.com/research/jsc97m/global ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, ... their offering. --> http://www.researchandmarkets.com/research/jsc97m/global ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, ... their offering. --> Research ...
(Date:2/5/2016)... --> --> ... the global active pharmaceuticals ingredients (APIs) market stood at ... US$185.9 bn by 2020. It is expected to expand ... The title of the report is "Active Pharmaceutical Ingredients ... by Therapeutic Area) - Global Industry Analysis, Size, Share, ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps ... in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally ... one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends to feel uncomfortable about ... than regular municipal or well water. The recent experience with lead contaminated water in ... a long way toward increasing public acceptance of recycled waste water as drinking water. ...
(Date:2/5/2016)... ... ... Give To Cure today announced that it is working with ... Cure’s campaign that is crowdfunding clinical trials to help find cures faster for Alzheimer’s ... smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point Consulting, ... in KLAS: Software & Services for HIT Implementation Support & Staffing report with ... ranks vendor performance by healthcare executives, managers and clinicians representing over 4,500 hospitals ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Dr. Justin Scott ... their 2nd Annual No Cost Dental Day to individuals in need. The event is ... of this No Cost Dental Day is to provide dental care to community members ...
Breaking Medicine News(10 mins):